돼지 백신 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 종류별, 투여 경로별, 지역별, 부문별 예측(2025-2030년)

Swine Vaccines Market Growth & Trends:

The global swine vaccines market size is expected to reach USD 2.41 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness a lucrative CAGR of 5.51% from 2025 to 2030. The increasing prevalence and incidence of swine diseases, rising concerns over zoonoses, and strengthening biosecurity measures among swine farms are some of the major factors augmenting the market growth. In addition, the initiatives taken by government and animal healthcare organizations in spreading disease awareness and supporting vaccination drives are further propelling the market growth during the projected period.

The Covid-19 pandemic has directly or indirectly impacted the key player's swine vaccine business operations and resulted in declined financial performance during the initial time. The effect of the pandemic with various production and supply chain bottlenecks delayed the delivery of necessary raw materials or active ingredients and postponed certain research & development activities. However, the simultaneously reported African swine fever outbreaks in several regions pressured the swine vaccine manufacturers with a large demand. In 2020, the OIE reported 9,928 ASF outbreaks in Asia, followed by 4,271 outbreaks in Europe. Hence, considering the situation, the government supported the distribution of swine vaccines with ease of restrictions, which afforded opportunities to rebuild the company's growth.

In addition, the global concern regarding antibiotic resistance is growing in agriculture and veterinary medicine. Thus, several countries have banned the use of antibiotics for livestock farming, including preventive treatment procedures. This act has compelled swine farms to adopt antibiotic-free disease preventive approaches such as vaccination. Furthermore, growing investments by key players to develop advanced products for better diagnosis are likely to propel market growth. For instance, in May 2020, Indian Immunologicals Ltd. introduced the Classical Swine Fever vaccine under the brand name 'Raksha Class', a unique cell culture technology-based vaccine developed in cooperation with the Indian Veterinary Research Institute, Bareilly.

Key players in the market are implementing various strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, among others to maintain a competitive edge in the market. For instance, In March 2022, Ceva launched the sow vaccine, a vaccine containing seven antigens used to treat neonatal diarrhea.

Swine Vaccines Market Report Highlights:

• The Inactivated (Killed) segment led the market with the largest revenue share of 52.03% in 2024. This is attributed to its easy availability, low cost, and stability advantages over live-attenuated vaccines.
• Based on disease type, the PRRS (Porcine Reproductive and Respiratory Syndrome) led the market with the largest revenue share of 14.26% in 2024.
• Based on route of administration, the injectable segment led the market with the largest revenue share of 75.79% in 2024, due to its efficiency and effectiveness in providing long-lasting protection against major diseases in pigs.
• Based on distribution channel, the hospital/clinic pharmacies segment accounted for the largest revenue share in 2024, due to their direct engagement with end-users, immediate vaccination services, and comprehensive healthcare solutions, ensuring timely vaccine distribution and effective disease management in the livestock sector.
• North America dominated the swine vaccines market with the largest revenue share of 38.46% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Type
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Swine Vaccines Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising concern about zoonoses & strengthening biosecurity
    • 3.2.1.2. Vaccines act as an alternative to antibiotics
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Supply bans on live pigs and pork products
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Political Landscape
    • 3.3.3.1. Economic Landscape
    • 3.3.3.2. Social Landscape
    • 3.3.3.3. Technology Landscape
    • 3.3.3.4. Legal Landscape
    • 3.3.3.5. Environmental Landscape
    • 3.3.3.6. Regulatory Landscape
  • 3.3.4. Product Pipeline Analysis
  • 3.3.5. Covid-19 Analysis
  • 3.3.6. Estimated Pig population by key countries, 2018 to 2024

Chapter 4. Swine Vaccines Market: Product Business Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Modified/Attenuated Live
  • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Inactivated (Killed)
  • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Swine Vaccines Market: Disease Type Business Analysis

• 5.1. Disease Type Market Share, 2024 & 2030
• 5.2. Disease Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2018 to 2030 (USD Million)
• 5.4. Swine Influenza
  • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Classical Swine Fever
  • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Porcine Parvovirus
  • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Porcine Circovirus Type 2
  • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. M.Hyo
  • 5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Actinobacillus Pleuropneumonia
  • 5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. PRRS
  • 5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.11. Foot & Mouth Disease
  • 5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.12. Pseudorabies
  • 5.12.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.13. PEDV
  • 5.13.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Swine Vaccines Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Injectables
  • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Intranasal
  • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Oral
  • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Swine Vaccines Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Retail
  • 7.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. E-commerce
  • 7.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Hospital/Clinic Pharmacies
  • 7.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Swine Vaccines Market: Regional Estimates & Trend Analysis by Product, Disease Type, Route of Administration, and Distribution Channel

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. U.S. swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Canada swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Mexico swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. UK swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Germany swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. France swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Italy swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Spain swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Norway swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Denmark swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Sweden
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Sweden swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Japan swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. China swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. India swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. South Korea swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. Australia
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Australia swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Thailand swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Brazil swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Argentina swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. South Africa swine vaccines market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Merck & Co., Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial performance
    • 9.5.1.3. Product benchmarking
    • 9.5.1.4. Strategic initiatives
  • 9.5.2. Ceva
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial performance
    • 9.5.2.3. Product benchmarking
    • 9.5.2.4. Strategic initiatives
  • 9.5.3. Zoetis
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial performance
    • 9.5.3.3. Product benchmarking
    • 9.5.3.4. Strategic initiatives
  • 9.5.4. Boehringer Ingelheim GmbH
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial performance
    • 9.5.4.3. Product benchmarking
    • 9.5.4.4. Strategic initiatives
  • 9.5.5. Elanco
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial performance
    • 9.5.5.3. Product benchmarking
    • 9.5.5.4. Strategic initiatives
  • 9.5.6. Indian Immunologicals Ltd.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial performance
    • 9.5.6.3. Product benchmarking
    • 9.5.6.4. Strategic initiatives
  • 9.5.7. BiogenesisBago
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial performance
    • 9.5.7.3. Product benchmarking
    • 9.5.7.4. Strategic initiatives
  • 9.5.8. Phibro Animal Health
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial performance
    • 9.5.8.3. Product benchmarking
    • 9.5.8.4. Strategic initiatives
  • 9.5.9. KM Biologics
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial performance
    • 9.5.9.3. Product benchmarking
    • 9.5.9.4. Strategic initiatives
  • 9.5.10. HIPRA
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial performance
    • 9.5.10.3. Product benchmarking
    • 9.5.10.4. Strategic initiatives
  • 9.5.11. Virbac
    • 9.5.11.1. Overview
    • 9.5.11.2. Financial performance
    • 9.5.11.3. Product benchmarking
    • 9.5.11.4. Strategic initiatives

Chapter 10. Key Takeaways